DexCom, Inc. will showcase for the first time its new global portfolio of real-time continuous glucose monitoring (CGM) systems at the 15thInternational Conference on Advanced Technologies and Treatments for Diabetes (ATTD) held April 27-30, 2022 in Barcelona. The expanded portfolio includes Dexcom ONE, Dexcom G6 and the upcoming Dexcom G7, a range of exceptionally accurate, real-time CGM systems designed to empower more people living with diabetes than ever before. Each system in the portfolio offers a different set of features and functionality for various needs across diabetes management; however, all three Dexcom systems eliminate burdensome scanning and painful fingerpricks† for calibration and diabetes treatment decisions.

The Dexcom Real-Time CGM Portfolio: Dexcom G7: Sensor - Smallest sensor size; All-in-one sensor and transmitter; 30 min warm up; 12-hour grace period; 10-day wear. Alerts: Highly customizable alerts; Silent mode; and Urgent low soon alert. Connectivity: Smartphone and smartwatch compatible; Optional receiver; Up to 10 remote followers; Clarity available in app; Future insulin pump integration.

Dexcom G6: Sensor - Small sensor size; 2-hour warm up; and 10-day wear. Alerts: Customizable alerts; and Urgent low soon alert. Connectivity: Smartphone and smartwatch compatible; Optional receiver; Up to 10 remote followers; Seamless insulin pump integration.

Dexcom ONE: Sensor - Small sensor size; 2-hour warm up; and 10-day wear. Alerts: Customizable alerts. Connectivity: Smartphone and smartwatch compatible.